Key Highlights

  • Curis (NASDAQ:CRIS) was quoted at USD 0.95 in premarket trading on November 5, 2026, down 14.5%, per the premarket quote.
  • Cash was USD 5.1 million at June 30, 2026, and the 10-Q states substantial doubt about the company's ability to continue as a going concern.
  • An August 2026 public offering raised estimated net proceeds of about USD 4.8 million at USD 1.50 per share, above the USD 0.95 premarket quote.
  • A 1-for-20 Reverse Stock Split took effect on July 6, 2026, and initial frontline CLL data for emavusertib are expected in December 2026.

August Offering After the Reverse Split

The most recent major financing at Curis was a public offering completed in August 2026, with estimated net proceeds of about USD 4.8 million. The company sold 335,001 shares at USD 1.50 each, plus pre-funded warrants for 3,398,333 shares at USD 1.49, and each investor received a five-year common Warrant exercisable at USD 1.75. It followed a 1-for-20 reverse stock split effective July 6, 2026, which consolidates 20 old shares into one and lifts the quoted price without changing company value. Shares outstanding were 2,090,077 as of August 11, 2026. The shares of Curis (NASDAQ:CRIS) were quoted lower in premarket trading on November 5, 2026, and no new company announcement for that day was found.

Financials, Going Concern and Pipeline

In the quarter ended June 30, 2026, Curis reported a net loss of USD 8.6 million and an operating loss of USD 9.9 million, with cash of USD 5.1 million plus USD 544,000 of restricted cash. The company concluded there is substantial doubt about its ability to continue as a going concern and that cash plus the August proceeds still fall short of funding twelve months of operations. Revenue ended after the November 2025 sale of its Erivedge Royalty rights, so spending is funded by Capital raises. The lead asset is emavusertib, an IRAK4 and FLT3 inhibitor. The fifth patient in the Phase 2 CLL trial combining it with zanubrutinib was dosed, announced July 30, 2026, and the first-quarter filing guided to initial data in December 2026.

Risks and What to Watch

Dilution is the central risk: pre-funded warrants and common warrants can add shares, and the company says it expects to raise substantial additional capital. A price of USD 0.95 is below the USD 1.00 minimum bid that Nasdaq requires for continued listing, although no deficiency notice was found in the filings reviewed. Clinical data can move a biotech sharply in either direction, and an early cohort of patients is a small basis for conclusions. As a micro-cap, a small number of trades can move the price, spreads can be wide and quoted moves can reverse, so the premarket decline should not be read as a trend. Watch the third-quarter filing for cash and runway, any new financing and the December data.

Where Things Stand

The 14.5% premarket decline at Curis (NASDAQ:CRIS) is best explained by financing and dilution risk, since the company has not linked the move to any announcement and the quote sits below the USD 1.50 August offering price. The balance of evidence is a micro-cap oncology company with limited cash, going concern doubt and a single lead program, where clinical data in December 2026 are the main upside catalyst. The next filing to watch is the third-quarter report for cash, runway and any new capital raise.